Pomerantz Files Class Action Against Fractyl Health (GUTS)
Pomerantz LLP has filed a federal class action lawsuit against Fractyl Health and certain officers in the Southern District court.
Pomerantz LLP announced the filing of a securities class action lawsuit against Fractyl Health, Inc., traded on the Nasdaq under the ticker symbol GUTS, and certain of its officers, according to a statement released September 24, 2026.
The suit was filed in the United States District Court for the Southern District, though the specific allegations against the company and its named officers were not detailed in the announcement. Class action suits of this type typically allege that investors suffered losses due to materially misleading statements or omissions by the defendant company or its leadership.
Read more Ormat Wins $35M DOE Grant for Geothermal Projects in Nevada, Utah →
Fractyl Health is a biotech company whose Nasdaq listing under the GUTS ticker has attracted investor attention. Securities class actions against publicly traded firms can draw in shareholders who bought stock during a defined period, known as the class period, if courts certify the case to proceed as a class.
Pomerantz LLP, a law firm with a focus on securities, corporate, and antitrust class action litigation, serves as lead counsel in the case. Investors who believe they may have suffered losses related to Fractyl Health shares are typically encouraged to contact the firm to evaluate potential claims.
Continue reading at All Financial Services & Investing.
